Publications Office of the EU
Spain-Vitoria-Gasteiz: Vaccines - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates text translated automatically in your browsing language

Spain-Vitoria-Gasteiz: Vaccines

  • Published
    07/10/2015
  • Deadline
    12/11/2015
  • Opening of tenders
    20/11/2015
  • Awarded
    09/02/2016
  • Today
    12/08/2026
Status
Awarded
Type of contract
Supplies
Subject for Renewal
No
Buyer
Gobierno Vasco-Eusko Jaurlaritza, Departamento de Salud, Dirección de Régimen Jurídico, Económico y Servicios Generales
Place of performance
NUTS code: ES21 País Vasco
Location of buyer
NUTS code: Not available
Business sector (Main CPV)
33651600 Vaccines
Total estimated contract value (excluding VAT)
981,225.00 EUR
Total final contract value (excluding VAT)
392,490.00 EUR
Tender reference number
6/2016-S
Description

Purchase of vaccine against Adult-Difteria type (Td).

Submission Method
Not available
Tenders may be submitted
Submission for all lots
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
20/11/2015 12:00
Place of performance
Award method
The most economic tender
Estimated value
981,225.00 EUR
Final contracted value
392,490.00 EUR
Award of contract
Official name: Glaxosmithkline, S.A.
Postal address:
Town:
Postal code:
Country: ESP
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.